Sarepta Therapeutics, Inc. Q4 and Full-Year 2021 Earnings Conference Call Forward Looking Statements

Tuesday, March 1, 2022 – 4:30 p.m. Eastern Time

In order to provide Sarepta's investors with an understanding of its current results and future prospects, forward-looking statements will be made during this conference call. Any statements made by Sarepta that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believe," "anticipate," "plan," "expect," "will," "may," "intend," "prepare," "look," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements relating to our future operations, financial performance and projections, business plans, market opportunities, priorities, research and development programs, and the potential benefits of our product candidates; the potentially transformative benefits of SRP-9001, including the potential for SRP-9001 to alter the trajectory of Duchenne, improve function, quality of life and prevent premature and early death; our expectation that the treatment benefit of SRP-9001 will continue to increase over time due to the progressive nature of Duchenne; our mission to translate the very best science into the very best treatments for patients in the shortest time possible; the potential for our therapies to be potentially life-enhancing across multiple platforms, including RNA, gene therapy and gene editing; our expectation to continue growing our internal research capabilities to position ourselves for sustained growth into the future; the potential for our products to benefit nearly 30% of individuals living with Duchenne; our belief that our balance sheet, based on current assumptions, provides us runway beyond the readout of study 301 of SRP-9001 and into 2024; our guidance for our product revenue of greater than $800 million dollars; our expectation that the growth rate for VYONDYS 53 will continue modestly in the coming quarters; our belief that there is a strengthening growth trajectory for AMONDYS 45 in the coming quarters; our expectation that, if our late-stage clinical programs are successful, we can achieve profitability by the end of 2024 and our yearly revenue can potentially reach $4 billion by 2025; the potential, if our pipeline is successful, for our product revenue to approach $10 billion generated from internal programs alone by the end of this decade; the potential benefits of our collaborations and partnerships, including the potential of GenEdit's polymer nanoparticles to deliver therapeutic cargo to muscle tissue after systemic administration to allow for targeted, non-viral systemic delivery of genetic medicines; the potential to use protein expression as an endpoint for accelerated approval in the U.S. and for conditional approval in Europe for SRP-9003; and expected milestones and plans, including performing an integrated analysis of 1-year data from studies 101, 102 and 103 for all patients who received the target dose and to share the totality of these results with regulators and then presenting all of these results at a medical meeting thereafter, sharing what we believe to be an impressive body of data we have generated to date at the upcoming MDA Clinical & Scientific Conference, discussing with OTAT the design of a registrational study for SRP-9003 after we optimize our process development and scale-up for our final commercially representative SRP-9003 material, having Part B of MOMENTUM serve as our pivotal study for SRP-5051, and if successful, seeking accelerated approval, and fully enrolling Part B of MOMENTUM in the second half of 2022.

These forward-looking statements involve risks and uncertainties, many of which are beyond our control. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: we may not be able to meet expectations with respect to sales of our products or attain the anticipated net revenues, profitability or positive cash-flow from operations; we may not be able to comply with all FDA post-approval commitments and requirements with respect to our products in a timely manner or at all; our dependence on certain manufacturers to produce our products and product candidates, including any inability on our part to accurately anticipate product demand and timely secure manufacturing capacity to meet product demand, may impair the availability of product to successfully support various programs; our data for SRP-5051, SRP-9001, the LGMD programs, including SRP-9003, and/or other programs may not be sufficient for obtaining regulatory approval; success in preclinical and clinical trials, especially if based on a small patient sample, does not ensure that later clinical trials will be successful, and the results of future research may not be consistent with past positive results or may fail to meet regulatory approval requirements for the safety and efficacy of product candidates; the commencement and completion of our clinical trials and announcement of results may be delayed or prevented for a number of reasons, including, among others, denial by the regulatory agencies of permission to proceed with our clinical trials, or placement of a clinical trial on hold, challenges in identifying, recruiting, enrolling and retaining patients to participate in clinical trials and inadequate quantity or quality of supplies of a product candidate or other materials necessary to conduct clinical trials; if the actual number of patients living with the diseases we aim to treat is smaller than estimated, our revenue and ability to achieve profitability may be adversely affected; we may not be able to execute on our business plans, including meeting our expected or planned regulatory milestones and timelines, research and clinical development plans, and bringing our product candidates to market, for various reasons, many of which may be outside of our control, including possible limitations of company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, regulatory, court or agency decisions, such as decisions by the United States Patent and Trademark Office with respect to patents that cover our product candidates, and the ongoing COVID-19 pandemic; and those risks identified under the heading "Risk Factors" in our most recent Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company which you are encouraged to review.

Any of the foregoing risks could materially and adversely affect the Company's business, results of operations and the trading price of Sarepta's common stock. You should not place undue reliance on forward-looking statements. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except to the extent required by applicable law or SEC rules.